Accès ouvert déclaré 2026 article

Nucleoprotein and glycoprotein based serological assays for detection of Marburg virus infections

James Kagame, Markus H. Kainulainen, Emmanuel Kabalisa, Polina Brangel, Jean Marie Uwimana, Jessica R. Harmon, Nouh Saad Mohamed, Jean Luc Benimana, Ange Umwari, Elif Karaaslan, Agnes Gasengayire, Jennifer Akimana, Herve Murenzi, Claudine Kabageni, Tara Sealy, Bruce Rwagitinywa, Misbah Gashegu, Ayman Ahmed, Shilpi Jain, César G. Albariño, Mary Joung Choi, Amy J. Schuh, Tsion Firew, Enock Karekezi, Richard C.N. Mwesigwa, Albert Tuyishime, Jonathan S. Towner, Thierry H. Roels, Isabelle Mukagatare, William E. Dowling, Joel M. Montgomery, Claude Mambo Muvunyi, Christina F. Spiropoulou, Jean Claude Semuto Ngabonziza, Eric Bergeron

1Citations signalées, ce qui n’est pas une note de qualité

7Institutions déclarées

3Pays d’affiliation déclarés

Rattachement africain : Rwanda, us, no. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: Marburg virus disease (MVD) is a rare but highly fatal zoonotic illness. Current serological tools are limited by their reliance on glycoprotein (GP)-based antigens or Marburg virus infected cell lysates, which cannot distinguish natural infection induced immune responses from GP-based vaccines. This diagnostic gap complicates the detection of missed cases particularly in areas of high vaccination coverage. METHODS: We developed and validated two complementary assays: a nucleoprotein C-terminal tail (NPct) Mix-and-Read (MR) assay and a recombinant GP1,2ΔTM ELISA. Serum samples used for validation were collected 6-9 months after the 2024 Rwanda MVD outbreak from RT-PCR-confirmed recovered patients (n = 36) and uninfected contacts (n = 46). Assay validation included additional serum controls from pre-outbreak Rwandan samples, Ebola virus disease recovered patients, and Rousettus aegyptiacus bats experimentally infected with MARV. Receiver operating characteristic (ROC) curve analyses were used to assess clinical accuracy. FINDINGS: The MARV anti-NPct MR assay demonstrated near-perfect discrimination between cases and controls with an area under the curve (AUC) = 0.996 (95% CI, 0.990-1.000), and yielding performance of 94.4% clinical sensitivity (95% CI, 81.9-99.0%) and 99.7% specificity (95% CI, 98.1-100.0%), and no cross-reactivity with Ebola convalescent sera. The MARV GP ELISA achieved 94.4% clinical sensitivity (95% CI, 81.9-99.0%) and 100% specificity (95% CI, 92.3-100%) with an AUC 0.973 (95% CI, 0.922-1.000). Both assays produced concordant results for all samples tested. In experimentally infected bats, the MARV anti-NPct MR assay achieved 100% sensitivity and 100% specificity. INTERPRETATION: The MARV anti-NPct MR assay provides a rapid, high-throughput, species-agnostic tool expected to differentiate natural infection from vaccine-induced immunity, addressing a critical gap in the current MVD diagnostic pipeline. Its robust validation in the largest cohort of recovered patients to date and applicability to reservoir hosts highlight its broad utility for outbreak response, follow-up care, and ecological studies. FUNDING: This work was supported by funding from US Centers for Disease Control and prevention, the Coalition for Epidemic Preparedness Innovations (CEPI), and Rwanda Biomedical Centre.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: Nucleoprotein and glycoprotein based serological assays for detection of Marburg virus infections
Date Crossref: 01/05/2026
Éditeur: Elsevier BV
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

Rwanda Biomedical Center Rwanda (code pays fourni par la source)
Établissement de santé
Centers for Disease Control and Prevention pays non établi dans la notice
Organisme public
Coalition for Epidemic Preparedness Innovations pays non établi dans la notice
Structure de recherche
Africa Health Sciences University Kigali, Rwanda (code pays fourni par la source)
Université ou école supérieure
King Faisal Hospital Rwanda Rwanda (code pays fourni par la source)
Établissement de santé
University of Kigali University of Kigali, Rwanda (code pays fourni par la source)
Université ou école supérieure
University of Georgia pays non établi dans la notice
Université ou école supérieure
Rwanda Biomedical Centre Kigali, Rwanda (pays nommé en fin d’affiliation)
Institution
Viral Special Pathogens Branch pays non établi dans la notice
Institution
US CDC Kigali, Rwanda (pays nommé en fin d’affiliation)
Institution
University of Rwanda Department of Clinical Biology Kigali, Rwanda (pays nommé en fin d’affiliation)
Université ou école supérieure
College of Pharmacy Department of Pharmaceutical and Biomedical Sciences pays non établi dans la notice
Université ou école supérieure

Rwanda Biomedical Center (Rwanda), Centers for Disease Control and Prevention et Coalition for Epidemic Preparedness Innovations, avec 9 autres affiliations. Pays d’affiliation : Rwanda.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Viral Infections and Outbreaks Researchvaccines and immunoinformatics approachesBacillus and Francisella bacterial research

Lire en accès ouvert Consulter la publication primaire Ouvrir le DOI